[1]杨雪 相萍萍 陈国芳 刘超.IGF-1在代谢性疾病中的作用[J].国际内分泌代谢杂志,2018,38(01):33-25.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
　Yang Xue,Xiang Pingping,Chen Guofang,et al.Effects of IGF-1 in metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(01):33-25.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
点击复制

IGF-1在代谢性疾病中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年01期
页码:
33-25
栏目:
综述
出版日期:
2018-01-20

文章信息/Info

Title:
Effects of IGF-1 in metabolic diseases
作者:
杨雪 相萍萍 陈国芳 刘超
210028 南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏省中医药研究院
Author(s):
Yang Xue;  Xiang Pingping;  Chen Guofang;  Liu Chao
Department of Endocrinology and Metabolism, Affiliated Hospital of Traditional Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China
关键词:
胰岛素样生长因子-1;  代谢性疾病;  糖尿病
Keywords:
Insulin growth factor-1;  Metabolic diseases;  Diabetes mellitus
DOI:
10.3760/cma.j.issn.1673-4157.2018.01.009
摘要:
胰岛素样生长因子(IGF)-1是一种重要的生长刺激因子,具有胰岛素样作用,可促进细胞生长、发育,参与机体多种生理、病理过程。IGF-1参与矮小症、肥胖、2型糖尿病、代谢性骨病等代谢性疾病的发生、发展。同时IGF-1的作用还包括促进儿童骨骼生长发育; 促进脂肪分解; 反映胰岛素抵抗的严重程度、改善胰岛素敏感性; 增强骨密度、防止骨质疏松。
Abstract:
Insulin growth factor 1(IGF-1)is an important growth stimulating factor, with insulin-like action, which can promote cell growth, development, participate in a variety of physiological and pathological processes. IGF-1 is involved in the development of metabolic diseases such as short stature, obesity, type 2 diabetes mellitus, metabolic bone disease and so on. At the same time, the effects of IGF-1 includes promoting the growth and development of children's porosis bone, promoting the decomposition of lipids, reflecting the severity of insulin resistance, improving insulin sensitivity, increasing bone density, and preventing osteoporosis.

参考文献/References:


[1] Cabail MZ,Li S,Lemmon E,et al. The insulin and IGF1 receptor kinase domains are functional dimers in the activated state[J].Nat Commun,2015,6:6406. DOI: 10.1038/ncomms7406.
[2] Rupp C, Scherzer M, Rudisch A, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction[J].Oncogene,2015,34(7):815-825. DOI:10.1038/onc.2014.18.
[3] Chen HS, Wu TE, Hsiao LC, et al. Interaction between glycaemic control and serum insulin-like growth factor 1 on the risk of retinopathy in type 2 diabetes[J].Eur J Clin Invest,2012,42(4):447-454. DOI:10.1111/j.1365-2362.2011.02616.x.
[4] Chang HR, Kim HJ, Xu X,et al. Macrophage and adipocyte IGF1 maintain adipose tissue homeostasis during metabolic stresses[J].Obesity(Silver Spring),2016,24(1):172-183. DOI:10.1002/oby.21354.
[5] Zhou Q, Li B, Zhao J,et al. IGF-I induces adipose derived mesenchymal cell chondrogenic differentiation in vitro and enhances chondrogenesis in vivo[J].In Vitro Cell Dev Biol Anim,2016,52(3):356-364. DOI:10.1007/s11626-015-9969-9.
[6] Donzeau A, Bouhours-Nouet N, Fauchard M, et al. Birth weight is associated with the IGF-1 response to GH in children: programming of the anabolic action of GH [J].J Clin Endocrinol Metab,2015,100(8):2972-2978.DOI:10.1210/jc.2015-1603.
[7] 高兰英, 于宝生, 王安茹, 等.血清胰岛素样生长因子-1 生 成试验在矮小症儿童诊断中的价值初探[J]. 儿科药学杂志, 2012, 18(12):13-15. DOI:10.3969/j.issn.1672-108X.2012.12.005.
[8] 朱丽虹,李国兴,邹萍. 胰岛素样生长因子-1与生长激素缺乏型矮身材的相关性分析[J]. 中外医学, 2016, 14(14): 57-58. DOI:10.14033/j.cnki.cfmr.2016.14.028.
[9] Chen L, Chen Q, Xie B,et al. Disruption of the AMPK-TBC1D1 nexus increases lipogenic gene expression and causes obesity in mice via promoting IGF1 secretion[J].Proc Natl Acad Sci U S A,2016,113(26):7219-7224. DOI:10.1073/pnas.1600581113.
[10] Bancu I,Navarro Díaz M,Serra A, et al.Low insulin-like growth factor-1 level in obesity nephropathy: a new risk factor[J].PLoS One,2016,11(5):e0154451.DOI:10.1371/journal.pone.0154451.
[11] Chang HR, Kim HJ, Xu X,et al. Macrophage and adipocyte IGF1 maintain adipose tissue homeostasis during metabolic stresses[J].Obesity(Silver Spring),2016,24(1):172-183. DOI:10.1002/oby.21354.
[12] Street ME, Smerieri A, Montanini L, et al. Interactions among pro-inflammatory cytokines, IGF system and thyroid function in pre-pubertal obese subjects[J].J Biol Regul Homeost Agents,2013,27(1):259-266.
[13] Cubbon RM,Kearney MT,Wheatcroft SB.Endothelial IGF-1 receptor signalling in diabetes and insulin resistance[J].Trends Endocrinol Metab,2016,27(2):96-104.DOI:10.1016/j.tem.2015.11.009.
[14] Nolan CJ, Ruderman NB, Kahn SE, et al. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes[J].Diabetes,2015,64(3):673-686.DOI:10.2337/db14-0694.
[15] Cheng CW, Villani V, Buono R,et al. Fasting-mimicking diet promotes Ngn3-driven β-cell regeneration to reverse diabetes[J].Cell,2017,168(5):775-788.e12.DOI:10.1016/j.cell.2017.01.040.
[16] Sharma S, Tandon VR, Mahajan S, et al. Obesity: friend or foe for osteoporosis[J].J Midlife Health,2014,5(1):6-9.DOI:10.4103/0976-7800.127782.
[17] Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, et al. Relationships between serum adipocyte hormones(adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients[J].J Bone Miner Metab,2014,32(4):400-404.DOI:10.1007/s00774-013-0511-4.
[18] Li F, Xing WH, Yang XJ, et al. Influence of polymorphisms in insulin-like growth factor-1 on the risk of osteoporosis in a Chinese postmenopausal female population[J].Int J Clin Exp Pathol,2015,8(5):5727-5732.
[19] 刘润萍, 孙丽莎, 陈秋. 胰岛素样生长因子1与糖尿病合并骨质疏松的关系研究进展[J]. 中国全科医学, 2013,16(3):237-239.DOI:10.3969/j.issn.1007-9572.2013.01.076.
[20] 张楠, 周永焘, 刘金煜.老年男性骨质疏松患者血清瘦素、胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3表达的临床意义[J].中国老年学杂志, 2016, 36(9): 2142-2144. DOI:10.3969/j.issn.1005-9202.2016.09.042.
[21] Lundin H, Sääf M, Strender LE,et al. High serum insulin-like growth factor-binding protein 1(IGFBP-1)is associated with high fracture risk independent of insulin-like growth factor 1(IGF-I)[J].Calcif Tissue Int,2016,99(4):333-339. DOI:10.1007/s00223-016-0152-4.
[22] Niemann I, Hannemann A, Nauck M, et al. The association between insulin-like growth factor Ⅰ and bone turnover markers in the general adult population[J].Bone,2013,56(1):184-190. DOI:10.1016/j.bone.2013.06.013.
[23] Poudyal H, Brown L. Osteoporosis and its association with non-gonadal hormones involved in hypertension, adiposity and hyperglycaemia[J].Curr Drug Targets,2013,14(14):1694-1706.
[24] de Souza KS, Ururahy MA, da Costa Oliveira YM,et al. Low bone mineral density in patients with type 1 diabetes: association with reduced expression of IGF1, IGF1R and TGF B 1 in peripheral blood mononuclear cells[J].Diabetes Metab Res Rev,2016,32(6):589-595. DOI:10.1002/dmrr.2772.
[25] 赵诸慧, 奚立, 程若倩.IGF-1对骨代谢的影响及其相关性研究[J].临床和实验医学杂志,2016,15(22): 2246-2249. DOI:10.3969/j.issn.1671-4695.2016.22.024.
[26] 肖飞, 陈聚伍, 王福建, 等. 胰岛素样生长因子1在家兔骨折愈合过程中的作用[J]. 中华实验外科杂志, 2013,30(9):1936-1938.DOI:10.3760/cma.j.issn.1001-9030.2013.09.055.

相似文献/References:

[1]艾华,谢岚.Irisin与代谢性疾病的关系[J].国际内分泌代谢杂志,2014,(05):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
　Ai Hua,Xie Lan.Relationship between irisin and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(01):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
[2]陈恺情,卜瑞芳.Irisin——可否让代谢性疾病治疗进入新时代[J].国际内分泌代谢杂志,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
　Chen Kaiqing,Bu Ruifang..Could irisin lead the treatment of metabolic diseases into a new era?[J].International Journal of Endocrinology and Metabolism,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
[3]谢绍锋,黄莉吉,王昆,等.南京市城区40岁以上人群超重、肥胖流行 特点调查分析[J].国际内分泌代谢杂志,2016,36(03):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
　Xie Shaofeng*,Huang Liji,Wang Kun,et al.Epidemiological investigation of overweight and obesity in population aged 40 years or older in Nanjing City[J].International Journal of Endocrinology and Metabolism,2016,36(01):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
[4]祝凌妃,杨震,秦利.肌肉因子与代谢性疾病[J].国际内分泌代谢杂志,2016,36(05):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
　Zhu Lingfei,Yang Zhen,Qin li.Myokines and metabolic disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
[5]项芬芬,张学梅,高英慧,等.p53与物质能量代谢的关系[J].国际内分泌代谢杂志,2017,37(04):262.
　Xiang Fenfen*,Zhang Xuemei,Gao Yinghui,et al.Relationship between p53 and material, energy metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(01):262.
[6]杨雪 韦晓 杨婉薇 陈国芳 刘超.代谢组学在糖尿病研究中的应用[J].国际内分泌代谢杂志,2018,38(05):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
　Yang Xue,Wei Xiao,Yang Wanwei,et al.Application of metabonomics in diabetic research[J].International Journal of Endocrinology and Metabolism,2018,38(01):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
[7]王佳蓓 陈风 刘莹 王涤非.Nur77与物质能量代谢的关系[J].国际内分泌代谢杂志,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
　Wang Jiabei,Chen Feng,Liu Ying,et al.Relationship between Nur77 and meterial, energy metabolism[J].International Journal of Endocrinology and Metabolism,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
[8]王雪 朱惠娟 龚凤英.棕色脂肪因子与代谢性疾病[J].国际内分泌代谢杂志,2019,39(06):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
　Wang Xue,Zhu Huijuan,Gong Fengying.Relationship between brown adipocytokine and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2019,39(01):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
[9]王鹏程,姜长涛.肠源神经酰胺与代谢性疾病[J].国际内分泌代谢杂志,2021,41(04):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
　Wang Pengcheng,Jiang Changtao..Relationship between intestinal ceramide and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2021,41(01):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
[10]乔晶,刘乙君,王彦.甘油三酯-葡萄糖指数与胰岛素抵抗相关代谢性疾病的关系[J].国际内分泌代谢杂志,2022,42(03):223.[doi:10.3760/cma.j.cn121383-20210206-02013]
　QiaoJing,LiuYijun,WangYan..Relationship between triglyceride-glucose index and insulin resistance-related metabolic diseases[J].International Journal of Endocrinology and Metabolism,2022,42(01):223.[doi:10.3760/cma.j.cn121383-20210206-02013]

备注/Memo

备注/Memo:

通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2018-01-30